Spots Global Cancer Trial Database for relapsed multiple myeloma
Every month we try and update this database with for relapsed multiple myeloma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of Venetoclax and ABBV-838 Combination Therapy With Dexamethasone in Participants With Multiple Myeloma Whose Cancer Has Come Back or Had No Response to Recent Cancer Treatment | NCT02951117 | Multiple Myelom... | Venetoclax ABBV-838 Dexamethasone | 18 Years - 99 Years | AbbVie | |
| Study to Evaluate the Safety and Efficacy of Pomalidomide Monotherapy in Subjects With Refractory or Relapsed Refractory Multiple Myeloma | NCT01324947 | Multiple Myelom... | pomalidomide | 18 Years - | Celgene | |
| A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma | NCT03314181 | Multiple Myelom... | Dexamethasone Daratumumab Venetoclax Bortezomib | 18 Years - | AbbVie | |
| Clinical Trial of Expanded and Activated Autologous NK Cells to Treat Multiple Myeloma | NCT02481934 | Multiple Myelom... | NKAE cells infu... Lenalidomide Bortezomib | 20 Years - 80 Years | Hospital Universitario 12 de Octubre | |
| MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide) | NCT06152575 | Multiple Myelom... | Elranatamab Elotuzumab Pomalidomide Dexamethasone Bortezomib Carfilzomib | 18 Years - | Pfizer | |
| MagnetisMM-5: Study of Elranatamab (PF-06863135) Monotherapy and Elranatamab + Daratumumab Versus Daratumumab + Pomalidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma | NCT05020236 | Multiple Myelom... | Elranatamab Daratumumab Pomalidomide Dexamethasone | 18 Years - | Pfizer | |
| Efficacy and Safety of Pomalidomide and Dexamethasone in RRMM Patients With Renal Insufficiency | NCT02045017 | Multiple Myelom... | Pomalidomide an... | 18 Years - | Celgene | |
| A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma. | NCT05228470 | Elranatamab Myeloma Multiple Myelom... Relapsed Multip... Refractory Mult... PF-06863135 BCMA Bispecific Bispecific Anti... BCMA-CD3 Bispec... MagnetisMM-8 | Elranatamab | 18 Years - | Pfizer | |
| A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma. | NCT05228470 | Elranatamab Myeloma Multiple Myelom... Relapsed Multip... Refractory Mult... PF-06863135 BCMA Bispecific Bispecific Anti... BCMA-CD3 Bispec... MagnetisMM-8 | Elranatamab | 18 Years - | Pfizer | |
| TKI258 in Subjects With Refractory or Relapsed Multiple Myeloma | NCT00243763 | Multiple Myelom... | TKI258 | 18 Years - | Novartis | |
| A Study to Assess Renal Function Response to Treatment in Patients With Relapsed Multiple Myeloma and Creatinine Clearance | NCT02849444 | Multiple Myelom... | Anti-myeloma tr... | 18 Years - | Celgene | |
| Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients | NCT01002248 | Multiple Myelom... | Perifosine Perifosine Plac... Bortezomib Dexamethasone | 18 Years - | AEterna Zentaris | |
| A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma | NCT01564537 | Relapsed Multip... Refractory Mult... | Ixazomib Lenalidomide Dexamethasone Placebo | 18 Years - | Takeda | |
| Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma | NCT01080391 | Relapsed Multip... | Dexamethasone Lenalidomide Carfilzomib | 18 Years - | Amgen | |
| A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma | NCT03314181 | Multiple Myelom... | Dexamethasone Daratumumab Venetoclax Bortezomib | 18 Years - | AbbVie | |
| PS-341 (VELCADE™) Versus High-Dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma | NCT00048230 | Multiple Myelom... | bortezomib | - | Millennium Pharmaceuticals, Inc. | |
| Safety and Efficacy of SDX-101 (R-Etodolac) in Patients With Relapsed or Refractory Multiple Myeloma (MM) | NCT00293111 | Multiple Myelom... | SDX-101 (R-Etod... | 18 Years - | Teva Branded Pharmaceutical Products R&D, Inc. | |
| A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma. | NCT05228470 | Elranatamab Myeloma Multiple Myelom... Relapsed Multip... Refractory Mult... PF-06863135 BCMA Bispecific Bispecific Anti... BCMA-CD3 Bispec... MagnetisMM-8 | Elranatamab | 18 Years - | Pfizer | |
| A Study Evaluating The Safety And Pharmacokinetics Of Escalating Doses Of RO7297089 In Patients With Relapsed Or Refractory Multiple Myeloma | NCT04434469 | Refractory Mult... Relapsed Multip... | RO7297089 | 18 Years - | Genentech, Inc. | |
| A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma | NCT02076009 | Multiple Myelom... | Daratumumab Lenalidomide Dexamethasone | 18 Years - | Janssen Research & Development, LLC | |
| Early Patient Access Single Named Patient Program for the Use of Ulocuplumab for the Treatment of Multiple Myeloma | NCT02666209 | Multiple Myelom... Multiple Myelom... | Ulocuplumab Lenalidomide Bortezomib Dexamethasone | 18 Years - | Dana-Farber Cancer Institute | |
| A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide in Combination With Low-Dose Dexamethasone Versus High-Dose Dexamethasone in Subjects With Refractory Multiple Myeloma or Relapsed and Refractory Multiple Myeloma and Companion Study | NCT01311687 | Multiple Myelom... | pomalidomide Dexamethasone | 18 Years - | Celgene | |
| Study of Belantamab Mafodotin in Combination With Kd for the Treatment of Relapsed Myeloma Patients, Refractory to Lenalidomide | NCT05060627 | Relapsed Multip... | Belantamab mafo... Carfilzomib Dexamethasone | 18 Years - | PETHEMA Foundation | |
| Dovitinib Combined With Bortezomib and Dexamethasone for Relapsed/Refractory Multiple Myeloma | NCT01680796 | Multiple Myelom... | Dovitinib Bortezomib Dexamethasone | 18 Years - | University of Florida | |
| PS-341 (VELCADE™) Versus High-Dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma | NCT00048230 | Multiple Myelom... | bortezomib | - | Millennium Pharmaceuticals, Inc. | |
| RAD001 and Lenalidomide in the Treatment of Subjects With Relapsed and Relapsed/Refractory Multiple Myeloma | NCT00729638 | Multiple Myelom... | RAD001 lenalidomide | 18 Years - | Massachusetts General Hospital | |
| A Study to Assess Renal Function Response to Treatment in Patients With Relapsed Multiple Myeloma and Creatinine Clearance | NCT02849444 | Multiple Myelom... | Anti-myeloma tr... | 18 Years - | Celgene | |
| Study of High Dose Carfilzomib in Multiple Myeloma Patients Who Have Progressed On Standard Dose Carfilzomib | NCT01775553 | Relapse Multipl... Refractory Mult... | Carfilzomib | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma | NCT05896228 | Refractory Mult... Relapsed Multip... | Iberdomide Carfilzomib Daratumumab Dexamethasone Acetaminophen Diphenhydramine Montelukast | 18 Years - 75 Years | University of Miami | |
| A Phase I Study Of Panobinostat/Lenalidomide/Bortezomib/Dex for Relapsed And Relapsed/Refractory Multiple Myeloma | NCT01965353 | Multiple Myelom... | Panobinostat Dexamethasone Lenalidomide Bortezomib | 18 Years - | Dana-Farber Cancer Institute | |
| Antiminor Histocompatibility Complex (MiHA) T Cells for Patients With Relapsed Hematologic Malignancies Following Matched HSCT (Guided Lymphocyte Immunopeptide Derived Expansion) | NCT03091933 | Hematologic Can... Relapse Leukemi... Relapsed Adult ... Relapsed Adult ... Relapsed CLL Relapsed Non Ho... Relapsed Hodgki... Relapsed Myelod... Relapsed Multip... | GLIDE | 18 Years - 65 Years | Ciusss de L'Est de l'Île de Montréal | |
| A Study of Motexafin Gadolinium for the Treatment of Relapsed or Refractory Multiple Myeloma | NCT00096837 | Multiple Myelom... | Motexafin Gadol... | 18 Years - | Pharmacyclics LLC. | |
| Study Testing Radium-223 Dichloride in Relapsed Multiple Myeloma | NCT02928029 | Multiple Myelom... | Radium-223 dich... Placebo Bortezomib Dexamethasone | 18 Years - | Bayer | |
| Study Evaluating the Safety and Tolerability of Weekly Dosing of Oral IXAZOMIB in Adult Patients With Relapsed and Refractory Multiple Myeloma | NCT00963820 | Multiple Myelom... | Ixazomib citrat... | 18 Years - | Takeda | |
| Bendamustine, Wkly Bortezomib, Lenalidomide and Dexamethasone for Multiple Myeloma | NCT01484626 | Multiple Myelom... | Bendamustine | 18 Years - | Loyola University | |
| Alternative Schedule of Velcade/Dexamethasone Plus Doxil for Patients With Multiple Myeloma | NCT00366106 | Multiple Myelom... | bortezomib dexamethasone doxorubicin HCl... | 18 Years - | Accelerated Community Oncology Research Network | |
| Antiminor Histocompatibility Complex (MiHA) T Cells for Patients With Relapsed Hematologic Malignancies Following Matched HSCT (Guided Lymphocyte Immunopeptide Derived Expansion) | NCT03091933 | Hematologic Can... Relapse Leukemi... Relapsed Adult ... Relapsed Adult ... Relapsed CLL Relapsed Non Ho... Relapsed Hodgki... Relapsed Myelod... Relapsed Multip... | GLIDE | 18 Years - 65 Years | Ciusss de L'Est de l'Île de Montréal | |
| A Study of PS-341 Given to Patients With Multiple Myeloma Who Experienced Progressive Disease After Receiving Dexamethasone in M34101-039 | NCT00063726 | Multiple Myelom... | bortezomib | 18 Years - | Millennium Pharmaceuticals, Inc. | |
| Dose-Escalation Study of ABBV-838, an Antibody Drug Conjugate, in Subjects With Relapsed and Refractory Multiple Myeloma | NCT02462525 | Multiple Myelom... | ABBV-838 Pomalidomide Dexamethasone | 18 Years - 99 Years | AbbVie | |
| Study of Melflufen (Melphalan Flufenamide) in Combination With Daratumumab in Relapsed-Refractory Multiple Myeloma | NCT04649060 | Relapsed Multip... Relapsed-Refrac... | Melflufen Dexamethasone Daratumumab | 18 Years - | Oncopeptides AB | |
| Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma. | NCT03158688 | Relapsed Multip... Refractory Mult... | Dexamethasone Daratumumab Carfilzomib | 18 Years - | Amgen | |
| Safety and Dose Study of GRN163L Administered to Treat Patients With Refractory or Relapsed Multiple Myeloma | NCT00594126 | Multiple Myelom... | Imetelstat Sodi... | 18 Years - | Geron Corporation | |
| Dose Escalation Study of MLN0128 in Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia | NCT01118689 | Relapsed Multip... Refractory Mult... Waldenstrom Mac... | MLN0128 | 18 Years - | Millennium Pharmaceuticals, Inc. | |
| Dovitinib Combined With Bortezomib and Dexamethasone for Relapsed/Refractory Multiple Myeloma | NCT01680796 | Multiple Myelom... | Dovitinib Bortezomib Dexamethasone | 18 Years - | University of Florida | |
| MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb | NCT04649359 | Multiple Myelom... | Elranatamab (PF... | 18 Years - | Pfizer | |
| Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma | NCT05896228 | Refractory Mult... Relapsed Multip... | Iberdomide Carfilzomib Daratumumab Dexamethasone Acetaminophen Diphenhydramine Montelukast | 18 Years - 75 Years | University of Miami | |
| Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma | NCT01497093 | Multiple Myelom... | Pomalidomide Bortezomib Dexamethasone | 18 Years - | Celgene | |
| Efficacy of Perifosine Alone and in Combination With Dexamethasone for Patients With Multiple Myeloma | NCT00375791 | Multiple Myelom... | perifosine dexamethasone | 18 Years - | AEterna Zentaris | |
| A Phase 1 Study in Subjects With Relapsed or Refractory Multiple Myeloma | NCT02561962 | Multiple Myelom... | AMG 224 | 18 Years - | Amgen | |
| Phase 1b Multicenter Study of Carfilzomib With Lenalidomide and Dexamethasone in Relapsed Multiple Myeloma | NCT00603447 | Relapsed Multip... | Carfilzomib Lenalidomide Dexamethasone | 18 Years - | Amgen | |
| A Open-label Study of Ultra-High Dose Dexamethasone for Relapsed Multiple Myeloma | NCT02402725 | Multiple Myelom... | Dexamethasone | 18 Years - | Boston Medical Center | |
| A Study to Learn About the Effectiveness of the Medicine Called Elranatamab in People With Relapsed Refractory Multiple Myeloma | NCT05932290 | Multiple Myelom... | Elranatamab Standard of car... | 18 Years - | Pfizer | |
| Lenalidomide and Low-Dose Dexamethasone in Patients With Previously Treated Multiple Myeloma and Kidney Dysfunction | NCT00790842 | Multiple Myelom... Plasma Cell Neo... | Lenalidomide Dexamethasone Anticoagulants | 18 Years - | PrECOG, LLC. | |
| Lenalidomide and Pidilizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma | NCT02077959 | Multiple Myelom... | lenalidomide pidilizumab pharmacological... laboratory biom... | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| ATRA, Celecoxib, and Itraconazole as Maintenance | NCT02401295 | Relapsed Multip... | ATRA Celecoxib Itraconazole | 18 Years - 75 Years | University of Iowa | |
| A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma | NCT01564537 | Relapsed Multip... Refractory Mult... | Ixazomib Lenalidomide Dexamethasone Placebo | 18 Years - | Takeda | |
| Dose Escalation Study of MLN0128 in Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia | NCT01118689 | Relapsed Multip... Refractory Mult... Waldenstrom Mac... | MLN0128 | 18 Years - | Millennium Pharmaceuticals, Inc. | |
| Alternative Schedule of Velcade/Dexamethasone Plus Doxil for Patients With Multiple Myeloma | NCT00366106 | Multiple Myelom... | bortezomib dexamethasone doxorubicin HCl... | 18 Years - | Accelerated Community Oncology Research Network | |
| MagnetisMM-5: Study of Elranatamab (PF-06863135) Monotherapy and Elranatamab + Daratumumab Versus Daratumumab + Pomalidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma | NCT05020236 | Multiple Myelom... | Elranatamab Daratumumab Pomalidomide Dexamethasone | 18 Years - | Pfizer | |
| A Study of Venetoclax and ABBV-838 Combination Therapy With Dexamethasone in Participants With Multiple Myeloma Whose Cancer Has Come Back or Had No Response to Recent Cancer Treatment | NCT02951117 | Multiple Myelom... | Venetoclax ABBV-838 Dexamethasone | 18 Years - 99 Years | AbbVie | |
| Safety and Dose Study of GRN163L and Velcade to Treat Patients With Refractory or Relapsed Myeloma | NCT00718601 | Multiple Myelom... | Imetelstat Sodi... | 18 Years - | Geron Corporation | |
| Clinical Trial of Expanded and Activated Autologous NK Cells to Treat Multiple Myeloma | NCT02481934 | Multiple Myelom... | NKAE cells infu... Lenalidomide Bortezomib | 20 Years - 80 Years | Hospital Universitario 12 de Octubre | |
| Elotuzumab, Selinexor, and Dexamethasone for Relapsed Refractory Multiple Myeloma | NCT05170789 | Relapsed Multip... Refractory Mult... | Elotuzumab, Sel... | 18 Years - | Tulane University | |
| Lenalidomide and Low-Dose Dexamethasone in Patients With Previously Treated Multiple Myeloma and Kidney Dysfunction | NCT00790842 | Multiple Myelom... Plasma Cell Neo... | Lenalidomide Dexamethasone Anticoagulants | 18 Years - | PrECOG, LLC. | |
| Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma | NCT01083602 | Relapsed and Bo... Refractory Mult... Multiple Myelom... | panobinostat bortezomib dexamethasone | 18 Years - | Novartis | |
| Safety and Dose Study of GRN163L and Velcade to Treat Patients With Refractory or Relapsed Myeloma | NCT00718601 | Multiple Myelom... | Imetelstat Sodi... | 18 Years - | Geron Corporation | |
| Safety and Efficacy of SDX-101 (R-Etodolac) in Patients With Relapsed or Refractory Multiple Myeloma (MM) | NCT00293111 | Multiple Myelom... | SDX-101 (R-Etod... | 18 Years - | Teva Branded Pharmaceutical Products R&D, Inc. | |
| Daratumumab in Combination With Lenalidomide and Dexamethasone in Relapsed and Relapsed-refractory Multiple Myeloma | NCT01615029 | Multiple Myelom... | Part 1 (Dose Es... Part 2 (Dose Ex... Lenalidomide Dexamethasone | 18 Years - | Janssen Research & Development, LLC | |
| Daratumumab in Combination With Lenalidomide and Dexamethasone in Relapsed and Relapsed-refractory Multiple Myeloma | NCT01615029 | Multiple Myelom... | Part 1 (Dose Es... Part 2 (Dose Ex... Lenalidomide Dexamethasone | 18 Years - | Janssen Research & Development, LLC | |
| Efficacy Study of ZD6474 to Treat Multiple Myeloma Cancer | NCT00047788 | Multiple Myelom... | ZD6474 VEGF-receptor t... | 18 Years - | Sanofi | |
| Vaccination With Peptides From Anti-apoptotic Proteins in Relapsed Multiple Myeloma | NCT01272466 | Relapsed Multip... | peptides derive... | 18 Years - 90 Years | Herlev Hospital | |
| Study Testing Radium-223 Dichloride in Relapsed Multiple Myeloma | NCT02928029 | Multiple Myelom... | Radium-223 dich... Placebo Bortezomib Dexamethasone | 18 Years - | Bayer | |
| Anti-BCMA Chimeric Antigen Receptor T Cells for Relapsed or Refractory Multiple Myeloma | NCT05577000 | Refractory Mult... Relapsed Multip... | Manufactured An... Fludarabine Cyclophosphamid... | 18 Years - | University of California, San Francisco | |
| Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma | NCT06348108 | Multiple Myelom... Refractory Mult... Relapsed Multip... | Talquetamab Iberdomide Dexamethasone Bone Marrow Bio... | 18 Years - | University of California, San Francisco | |
| A Study of Melphalan Flufenamide (Melflufen)-Dex or Pomalidomide-dex for RRMM Patients Refractory to Lenalidomide | NCT03151811 | Multiple Myelom... | Melflufen Pomalidomide Dexamethasone | 18 Years - | Oncopeptides AB | |
| Bortezomib, Lenalidomide, and Dexamethasone Combination Therapy for Patients With Relapsed or Relapsed and Refractory Multiple Myeloma | NCT00378209 | Multiple Myelom... | Bortezomib Lenalidomide Dexamethasone | 18 Years - | Dana-Farber Cancer Institute | |
| APRIL CAR T Cells (AUTO2) Targeting BCMA and TACI for the Treatment of Multiple Myeloma | NCT03287804 | Multiple Myelom... | AUTO2 | 18 Years - | Autolus Limited | |
| Treatment of Relapsed/Refractory Multiple Myeloma (rrMM) With Pomalidomide in Clinical Practice | NCT02555839 | Multiple Myelom... | Pomalidomide Dexamethasone Pomalidomide Dexamethasone Bortezomib | 18 Years - | Celgene | |
| APRIL CAR T Cells (AUTO2) Targeting BCMA and TACI for the Treatment of Multiple Myeloma | NCT03287804 | Multiple Myelom... | AUTO2 | 18 Years - | Autolus Limited | |
| A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of BMS-986393 in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma | NCT06121843 | Multiple Myelom... | BMS-986393 Alnuctamab Mezigdomide Iberdomide | 18 Years - | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
